Crinetics Pharmaceuticals logo

Crinetics PharmaceuticalsNASDAQ: CRNX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 July 2018

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$5.29 B
-9%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector
-17%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 4 min ago
$57.08+$1.00(+1.79%)

Dividend

No data over the past 3 years
$12.50 K$700.00 K

Analysts recommendations

Institutional Ownership

CRNX Latest News

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
globenewswire.com14 November 2024 Sentiment: POSITIVE

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
globenewswire.com12 November 2024 Sentiment: POSITIVE

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
globenewswire.com08 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500.0 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock. The offering is expected to close on or about October 10, 2024, subject to the satisfaction of customary closing conditions.

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
globenewswire.com08 October 2024 Sentiment: NEUTRAL

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
zacks.com08 August 2024 Sentiment: NEGATIVE

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.94 per share a year ago.

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
zacks.com01 August 2024 Sentiment: NEGATIVE

Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
globenewswire.com18 July 2024 Sentiment: POSITIVE

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
globenewswire.com18 June 2024 Sentiment: POSITIVE

Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.
globenewswire.com30 May 2024 Sentiment: POSITIVE

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs.

  • 1(current)

What type of business is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

What sector is Crinetics Pharmaceuticals in?

Crinetics Pharmaceuticals is in the Healthcare sector

What industry is Crinetics Pharmaceuticals in?

Crinetics Pharmaceuticals is in the Biotechnology industry

What country is Crinetics Pharmaceuticals from?

Crinetics Pharmaceuticals is headquartered in United States

When did Crinetics Pharmaceuticals go public?

Crinetics Pharmaceuticals initial public offering (IPO) was on 18 July 2018

What is Crinetics Pharmaceuticals website?

https://www.crinetics.com

Is Crinetics Pharmaceuticals in the S&P 500?

No, Crinetics Pharmaceuticals is not included in the S&P 500 index

Is Crinetics Pharmaceuticals in the NASDAQ 100?

No, Crinetics Pharmaceuticals is not included in the NASDAQ 100 index

Is Crinetics Pharmaceuticals in the Dow Jones?

No, Crinetics Pharmaceuticals is not included in the Dow Jones index

When was Crinetics Pharmaceuticals the previous earnings report?

No data

When does Crinetics Pharmaceuticals earnings report?

The next expected earnings date for Crinetics Pharmaceuticals is 28 February 2025